ENSC Live signaler | Maksimer profitt med Getagraph.com

KJøP 107502 min ago

@ $0.897

Utstedt: 14 feb 2024 @ 21:28

Avkastning: -34.84%

Forrige signal: feb 14 - 16:42

Forrige signal: Selg

Avkastning: -0.39 %

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Stats
Dagens volum	176 491
Gjennomsnittsvolum	540 200
Markedsverdi	4.28M
EPS	$0 ( 2024-04-04 )
Neste inntjeningsdato	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.120
ATR14	$0.0100 (1.71%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-02	Gower Bob G	Buy	90 287	Common Stock
2023-03-01	Gower Bob G	Buy	270 000	Common Stock
2023-02-28	Gower Bob G	Buy	109 300	Common Stock
2022-12-09	Gower Bob G	Buy	357 143	Common Stock
2022-12-09	Gower Bob G	Buy	714 286	Warrants

INSIDER POWER
99.26
Last 80 transactions
Buy: 23 095 136 \| Sell: 3 675 006

Volum Korrelasjon

Lang: 0.13 (neutral)

Kort: 0.26 (neutral)

Signal:(46.493) Neutral

Ensysce Biosciences, Inc. Korrelasjon

10 Mest positive korrelasjoner
SVAC	0.928
PAIC	0.905
PRVB	0.904
SVOK	0.878
ALR	0.862
TLGT	0.852
ALLR	0.847
LKCO	0.844
RDHL	0.843
ELEV	0.839

10 Mest negative korrelasjoner
NETE	-0.92
LWAC	-0.92
MDRRP	-0.916
SRAC	-0.904
WSBCP	-0.895
RAVN	-0.889
HNST	-0.889
OVBC	-0.886
MRBK	-0.885
MNSBP	-0.883

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Ensysce Biosciences, Inc. Korrelasjon - Valuta/Råvare

0.36
( neutral )

0.62
( weak )

0.00
( neutral )

-0.15
( neutral )

0.33
( neutral )

Ensysce Biosciences, Inc. Økonomi

Annual	2023
Omsetning:	$2.23M
Bruttogevinst:	$-5.36M (-240.17 %)
EPS:	$-4.69

FY	2023
Omsetning:	$2.23M
Bruttogevinst:	$-5.36M (-240.17 %)
EPS:	$-4.69

FY	2022
Omsetning:	$2.52M
Bruttogevinst:	$-17.31M (-686.08 %)
EPS:	$-138.73

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-29.60

Financial Reports:

No articles found.

Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.